A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Care, Matthew A ^a,b   Barrans, Sharon ^c   Worrillow, Lisa ^c   Jack, Andrew ^c   Westhead, David R ^b   Tooze, Reuben M ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c St James's Institute of Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ARID3A; TRANSCRIPTION FACTOR BATF; TRANSCRIPTION FACTOR TCF4; TRANSCRIPTION FACTOR ZBTB32; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CARCINOGENESIS; CHROMOSOME ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GERMINAL CENTER; LARGE CELL LYMPHOMA; MACHINE LEARNING; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE;

ARTIFICIAL INTELLIGENCE; B-LYMPHOCYTES; CELL SURVIVAL; CHROMOSOMES, HUMAN; COMPUTATIONAL BIOLOGY; FOCAL ADHESIONS; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84873728254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055895     Document Type: Article

References (64)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
2. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100: 9991-9996.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
4. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520-13525.
5. Lenz G, Wright G, Dave SS, Xiao W, Powell J, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. The New England journal of medicine 359: 2313-2323.
6. Lenz G, Staudt LM, (2010) Aggressive lymphomas. The New England journal of medicine 362: 1417-1429.
7. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, et al. (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nature genetics 43: 830-837.
8. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
9. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of Burkitt's lymphoma. The New England journal of medicine 354: 2431-2442.
10. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851-1861.
11. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. The New England journal of medicine 354: 2419-2430.
12. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, et al. (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118: 139-147.
13. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, et al. (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 117: 4836-4843.
14. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, et al. (2010) Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 116: e118-127.
15. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282.
16. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, et al. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15: 5494-5502.
17. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, et al. (2011) Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes reflecting tumor and microenvironment. Blood 118: 1350-1358.
18. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, et al. (2008) Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111: 5509-5514.
19. Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, et al. (2011) Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 3727-3732.
20. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, et al. (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112: 3425-3433.
21. Williams PM, Li R, Johnson NA, Wright G, Heath JD, et al. (2010) A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. The Journal of molecular diagnostics: JMD 12: 680-686.
22. Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, et al. (2012) Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. British journal of haematology 159: 441-453.
23. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, et al. (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 26: 2103-2113.
24. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721.
25. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, et al. (2010) Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 116: e118-127.
26. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, et al. (2012) Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 22: 359-372.
27. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, et al. (2010) GeneSigDB-a curated database of gene expression signatures. Nucleic acids research 38: D716-725.
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, et al. (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27: 1739-1740.
29. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434: 338-345.
30. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
31. Hall M, Eibe F, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA Data Mining Software: An Update. SIGKDD Explorations 11.
32. Team R (2008) R: A Language and Environment for Statistical Computing.: Vienna Austria R Foundation for Statistical Computing.
33. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunological reviews 210: 67-85.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
35. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119.
36. Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, et al. (2010) Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 24: 1487-1497.
37. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
38. Yin T, Cook D, Lawrence M, (2012) ggbio: an R package for extending the grammar of graphics for genomic data. Genome Biol 13: R77.
39. Wickham H (2009) Ggplot2: elegant graphics for data analysis. New York: Springer. viii, 212 p.
40. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, et al. (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106: 1770-1777.
41. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210: 67-85.
42. Basso K, Klein U, Niu H, Stolovitzky GA, Tu Y, et al. (2004) Tracking CD40 signaling during germinal center development. Blood 104: 4088-4096.
43. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, et al. (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 28-40.
44. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111: 3701-3713.
45. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92.
46. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, et al. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106: 3183-3190.
47. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, et al. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117: 5019-5032.
48. Ciofani M, Madar A, Galan C, Sellars M, Mace K, et al. (2012) A validated regulatory network for th17 cell specification. Cell 151: 289-303.
49. Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Wumesh KC, et al. (2012) Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490: 502-507.
50. Li P, Spolski R, Liao W, Wang L, Murphy TL, et al. (2012) BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490: 543-546.
51. Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, et al. (2012) A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338: 975-980.
52. Yang Y, Shaffer AL, 3rd, Emre NC, Ceribelli M, Zhang M, et al (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21: 723-737.
53. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, et al. (2008) IRF4 addiction in multiple myeloma. Nature 454: 226-231.
54. Shaffer AL, 3rd, Young RM, Staudt LM (2012) Pathogenesis of human B cell lymphomas. Annual review of immunology 30: 565-610.
55. Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, et al. (2012) In Vitro Generation of Long-lived Human Plasma Cells. Journal of Immunology.
56. Miaw SC, Choi A, Yu E, Kishikawa H, Ho IC, (2000) ROG, repressor of GATA, regulates the expression of cytokine genes. Immunity 12: 323-333.
57. Yoon HS, Scharer CD, Majumder P, Davis CW, Butler R, et al. (2012) ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells. Journal of Immunology 189: 2393-2403.
58. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, et al. (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103: 4251-4258.
59. Cahalan MD, Chandy KG, (2009) The functional network of ion channels in T lymphocytes. Immunological reviews 231: 59-87.
60. Wulff H, Knaus HG, Pennington M, Chandy KG, (2004) K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. Journal of Immunology 173: 776-786.
61. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 103: 17414-17419.
62. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America 105: 13520-13525.
63. Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, et al. (2008) Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 135: 37-48.
64. Nagasawa M, Schmidlin H, Hazekamp MG, Schotte R, Blom B, (2008) Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. European journal of immunology 38: 2389-2400.